Skip to main content

Table 2 Changes of serum lipids, apoA5 and hs-CRP levels in two groups

From: The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

 

Baseline

After 6 weeks

After 12 weeks

Statin group

Combination group

Statin group

Combination group

Statin group

Combination group

TC (mmol/L)

4.85 ± 0.90

4.92 ± 0.83

4.22 ± 0.88*

3.75 ± 0.65 *

4.12 ± 0.76†

3.39 ± 0.30†§

TG (mmol/L)

1.97 ± 1.02

1.91 ± 0.87

1.74 ± 0.71*

1.24 ± 0.54 *

1.62 ± 0.63†

1.15 ± 0.48†§

LDL-C (mmol/L)

3.00 ± 0.43

3.04 ± 0.46

2.30 ± 0.53*

2.06 ± 0.28 *

2.21 ± 0.55†

1.93 ± 0.29†§

HDL-C (mmol/L)

0.89 ± 0.22

0.93 ± 0.14

1.00 ± 0.26*

1.10 ± 0.13 *

1.05 ± 0.20†

1.14 ± 0.08†§

ApoA5 (ng/ml)

49.49 ± 1.59

49.50 ± 2.48

61.48 ± 6.00*

66.03 ± 8.79*

67.4 ± 5.50†

73.2 ± 6.67†§

Hs-CRP (mg/L)

3.97 ± 3.52

3.89 ± 2.96

2.01 ± 0.94*

1.61 ± 0.32*

2.03 ± 1.54*

1.62 ± 0.63*

  1. Note: TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein A5, hs-CRP high-sensitivity C-reactive protein.
  2. * p < 0.05, compared with baseline in the same group;
  3. p < 0.05, compared with 6 weeks in the same group;
  4. § p < 0.05, combination group versus statin group by repeated measures ANOVA analyses.